phendimetrazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anorexics	2122	634-03-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: phendimetrazine hydrochloride phendimetrazine (+)-Phendimetrazine antapentan mephenmetrazine sedafamen phendimetrazine tartrate phendimetrazine HCl	minor descriptor (66-86); file maintained to MORPHOLINES (66-86); on-line & INDEX MEDICUS search MORPHOLINES (66-86); RN given refers to parent cpd without isomeric designation Molecular weight: 191.27 Formula: C12H17NO CLOGP: 1.92 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -1.90 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

phendimetrazine hydrochloride
phendimetrazine
(+)-Phendimetrazine
antapentan
mephenmetrazine
sedafamen
phendimetrazine tartrate
phendimetrazine HCl

minor descriptor (66-86); file maintained to MORPHOLINES (66-86); on-line & INDEX MEDICUS search MORPHOLINES (66-86); RN given refers to parent cpd without isomeric designation

Molecular weight: 191.27
Formula: C12H17NO
CLOGP: 1.92
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -1.90
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	0	Hosey CM, Chan R, Benet LZ
S (Water solubility)	17 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
July 28, 1976	FDA	TG UNITED LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sudden cardiac death	96.71	67.07	13	77	2127	63486805

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sudden cardiac death	100.99	66.51	15	93	5210	79739070

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA PE	N0000175372	Appetite Suppression
FDA EPC	N0000175423	Sympathomimetic Amine Anorectic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D000697	Central Nervous System Stimulants
FDA PE	N0000175651	Increased Sympathetic Activity

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Obesity	indication	414916001	DOID:9970
Heart valve disorder	contraindication	368009	DOID:4079
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Mild pre-eclampsia	contraindication	41114007
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Pulmonary hypertension	contraindication	70995007	DOID:6432
Arteriosclerotic vascular disease	contraindication	72092001
Angina pectoris	contraindication	194828000
Syncope	contraindication	271594007
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.77	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	INHIBITOR			CHEMBL	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Kd	4.90	CHEMBL

External reference:

ID	Source
4018492	VUID
N0000146814	NUI
D02080	KEGG_DRUG
7635-51-0	SECONDARY_CAS_RN
50-58-8	SECONDARY_CAS_RN
4018491	VANDF
4018492	VANDF
4019885	VANDF
C0070549	UMLSCUI
CHEBI:8059	CHEBI
CHEMBL1615439	ChEMBL_ID
CHEMBL1744	ChEMBL_ID
DB01579	DRUGBANK_ID
CHEMBL2062163	ChEMBL_ID
CHEMBL1898523	ChEMBL_ID
30487	PUBCHEM_CID
982	INN_ID
C100294	MESH_SUPPLEMENTAL_RECORD_UI
AB2794W8KV	UNII
297716	RXNORM
2337	MMSL
5268	MMSL
d00809	MMSL
001869	NDDF
001870	NDDF
001871	NDDF
26945002	SNOMEDCT_US
373340007	SNOMEDCT_US
39142008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-4057	TABLET	35 mg	ORAL	ANDA	16 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-5254	CAPSULE, EXTENDED RELEASE	105 mg	ORAL	NDA	23 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-041	TABLET	35 mg	ORAL	ANDA	12 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	10702-045	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	10702-077	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	10702-078	TABLET	35 mg	ORAL	ANDA	13 sections
phendimetrazine tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	12634-028	TABLET	35 mg	ORAL	ANDA	21 sections
phendimetrazine tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	12634-539	TABLET	35 mg	ORAL	ANDA	22 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	12634-910	CAPSULE, EXTENDED RELEASE	105 mg	ORAL	NDA	23 sections
PHENDIMETRAZINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-642	TABLET	35 mg	ORAL	ANDA	11 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	17224-500	TABLET	35 mg	ORAL	ANDA	13 sections
PHENDIMETRAZINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	17224-501	TABLET	35 mg	ORAL	ANDA	16 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	17224-800	TABLET	35 mg	ORAL	ANDA	13 sections
PHENDIMETRAZINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	17224-831	CAPSULE, EXTENDED RELEASE	105 mg	ORAL	NDA	23 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	21695-597	TABLET	35 mg	ORAL	ANDA	10 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	33261-341	TABLET	35 mg	ORAL	ANDA	12 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	33261-390	CAPSULE, EXTENDED RELEASE	105 mg	ORAL	NDA	23 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	43063-510	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	43063-510	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	43063-510	TABLET	35 mg	ORAL	ANDA	13 sections
PHENDIMETRAZINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-892	CAPSULE, EXTENDED RELEASE	105 mg	ORAL	NDA	23 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0385	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0715	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0715	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0715	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2235	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2235	TABLET	35 mg	ORAL	ANDA	13 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2592	TABLET	35 mg	ORAL	ANDA	16 sections
Phendimetrazine Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3976	TABLET	35 mg	ORAL	ANDA	13 sections
PHENDIMETRAZINE TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3988	CAPSULE, EXTENDED RELEASE	105 mg	ORAL	NDA	23 sections